Alkermes plc

small molecule / long-acting injectable neuroscience

ALKS · Nasdaq · Ireland

Share price · ALKS

$46.85-2.63 (-5.32%) 3M

close as of 2026-11-18 · 24h delayed · vol 1.4M (0.8x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when ALKS's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 24 Sep 2026-3.2%

    Nothing announced by ALKS that day or the session before.

  2. 18 Sep 2026-7.1%
  3. 29 Jun 2026-4.6%
  4. 12 May 2026+8.0%
  5. 5 May 2026+6.1%
  6. 31 Mar 2026+17.3%
  7. 25 Feb 2026-7.0%
  8. 18 Feb 2026-2.7%

Share of unusual movement by asset

For each asset, the share of ALKS's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Alixorexton
events and moves
96%
Aripiprazole lauroxil (Aristada) (Aristada)
events and moves
3shown from 8 days
Olanzapine/samidorphan (Lybalvi) (Lybalvi)
events and moves
2shown from 8 days
Aripiprazole lauroxil (Aristada Initio) (Aristada Initio)
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—1%
Other company news (earnings, financing, releases naming no asset)—28%
Sessions with no dated event—65%

Assets

(6 total)
6Total Assets
5Approved
1Phase 3 / Filed
0Phase 1–2 / Early
6Diseases
Quick filter:
Showing 6 of 6 assets
Target & Modality
Approved
Dopamine D2/D3 and serotonin 5-HT1A receptorSmall molecule
Schizophrenia
Approved
Dopamine D2/D3 and serotonin 5-HT1A receptorSmall molecule
Schizophrenia
Approved
Nrf2 pathway (fumaric acid ester)Small molecule
Multiple Sclerosis
Approved
Opioid receptorSmall molecule
Substance Use Disorder
Opioid and Alcohol Dependence
Approved
Dopamine D2 and serotonin 5-HT2A receptors (antagonist); mu-opioid receptor (antagonist)Small molecule
SchizophreniaBipolar Disorder
Phase 3
Orexin-2 receptor (agonist)Small molecule
NarcolepsyIdiopathic Hypersomnia

Upcoming events

(7 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
November 2026 (1)
AlixorextonPhase 2Idiopathic Hypersomnia
Est. primary completion 2026-11 · NCT06843590 · CT.gov ↗
What to watch
2027 (4)
May 2027 (2)
AlixorextonPhase 3Narcolepsy Type 1
Est. primary completion 2027-05 · NCT07455383 · CT.gov ↗
What to watch
AlixorextonPhase 3Narcolepsy Type 2
Est. primary completion 2027-05 · NCT07502443 · CT.gov ↗
What to watch
June 2027 (1)
AlixorextonPhase 3Narcolepsy Type 1
Est. primary completion 2027-06 · NCT07540897 · CT.gov ↗
What to watch
September 2027 (1)
Olanzapine/samidorphan (Lybalvi)Phase 3Bipolar I Disorder, Schizophrenia
Est. primary completion 2027-09 · NCT04987229 · CT.gov ↗
What to watch
2030 (1)
June 2030 (1)
AlixorextonPhase 2/3Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia
Est. primary completion 2030-06 · NCT06767683 · CT.gov ↗
What to watch
2034 (1)
July 2034 (1)
Diroximel fumarate · VumerityPhase 3Relapsing Forms of Multiple Sclerosis
Est. primary completion 2034-07-28 · NCT07483632 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

12 November 2025Topline resultAlixorextonPhase 2 Vibrance-2 (NCT06555783) met its dual primary endpoints in narcolepsy type 2
21 July 2025Topline resultAlixorextonPhase 2 Vibrance-1 (NCT06358950) met its primary endpoint in narcolepsy type 1

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$480M$121M$631M+ $124M short-term inv.—$93M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$496M$113M$512M+ $145M short-term inv.—$145M operating cash flowreport ↗
2026-Q1$393M$103M$352M+ $160M short-term inv.$66M-$166M operating cash flowreport ↗
2025-Q3$394M$82M$616M+ $495M short-term inv.—$102M operating cash flowreport ↗
2025-Q2$391M$77M$521M+ $495M short-term inv.—$150M operating cash flowreport ↗
2025-Q1$307M$72M$400M+ $484M short-term inv.—$99M operating cash flowreport ↗
2024-Q3$378M$60M$396M+ $513M short-term inv.—$82M operating cash flowreport ↗
2024-Q2$399M$60M$535M+ $341M short-term inv.—$146M operating cash flowreport ↗
2024-Q1$350M$68M$421M+ $324M short-term inv.—$21M operating cash flowreport ↗
2023-Q3$381M$97M$648M+ $241M short-term inv.—$100M operating cash flowreport ↗
2023-Q2$617M$101M$666M+ $163M short-term inv.—$216M operating cash flowreport ↗
2023-Q1$288M$94M$321M+ $279M short-term inv.$42M-$21M operating cash flowreport ↗
2022-Q3$252M$100M$264M+ $316M short-term inv.$64M$0.6M operating cash flowreport ↗
2022-Q2$276M$93M$255M+ $326M short-term inv.$30M-$2.3M operating cash flowreport ↗
2022-Q1$279M$96M$283M+ $246M short-term inv.$36M$22M operating cash flowreport ↗
2021-Q3$294M$118M$310M+ $250M short-term inv.$29M$83M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$1.5B$324M$1.1B+ $200M short-term inv.—$521M operating cash flowreport ↗

For fiscal year 2025, Alkermes reported total revenues of $1,475.9M, down 5.2% YoY, with proprietary product net sales increasing approximately 9% YoY. R&D expense was $323.96M, up 32.1% YoY, and cash and equivalents totaled $1,119.78M. The company reported GAAP net income of $241.66M, or $1.43 diluted earnings per share.

For 2026, management guided to total revenues of $1,730–$1,840M, R&D expenses of $445–$485M, SG&A expenses of $890–$930M, a GAAP net loss of $115–$135M, EBITDA of $60–$90M, and adjusted EBITDA of $370–$410M. The Alixorexton Phase 3 program in narcolepsy is expected to initiate in Q1 2026, with the Phase 2 study in idiopathic hypersomnia continuing, and additional orexin candidates are planned to advance into Phase 2 in ADHD and fatigue associated with multiple sclerosis and Parkinson’s disease. The acquisition of Avadel closed in February 2026, with LUMRYZ net sales for the post-close period expected at $315–$335M for 2026.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$1.6B$245M$291M+ $461M short-term inv.—$439M operating cash flowreport ↗
2023-FY$1.7B$271M$457M+ $316M short-term inv.—$401M operating cash flowreport ↗
2022-FY$1.1B$394M$292M+ $316M short-term inv.$40M$21M operating cash flowreport ↗
2021-FY$1.2B$407M$338M+ $199M short-term inv.$12M$102M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 33 sales ($10.1M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-03Gaffin David Joseph · EVP, CLO, Alkermes, Inc.Open-market sale2,035$46.17$94KForm 4
2026-10-08Reed Joshua · SVP, Chief Financial OfficerOption exercise9,164——Form 4
2026-10-08Reed Joshua · SVP, Chief Financial OfficerTax withholding4,069$40.11$163KForm 4
2026-10-08Reed Joshua · SVP, Chief Financial OfficerOption exercise (derivative)9,164——Form 4
2026-10-07Whitaker Anne Clem · directorAward / grant (derivative)7,239——Form 4
2026-10-07Whitaker Anne Clem · directorAward / grant (derivative)17,998——Form 4
2026-10-02Gaffin David Joseph · EVP, CLO, Alkermes, Inc.Open-market sale2,034$41.03$83KForm 4
2026-09-03Gaffin David Joseph · EVP, CLO, Alkermes, Inc.Open-market sale2,034$48.01$98KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 383 reporting institutions held 175.4M shares ($5.9B).

#InstitutionSharesValue
1BlackRock, Inc.28,314,410$1.0B
2BAKER BROS. ADVISORS LP10,012,267$354.0M
3VANGUARD PORTFOLIO MANAGEMENT LLC9,511,112$336.3M
4STATE STREET CORP9,465,286$334.7M
5VANGUARD CAPITAL MANAGEMENT LLC7,427,397$262.6M
6RENAISSANCE TECHNOLOGIES LLC6,160,428$217.8M
7AMERICAN CENTURY COMPANIES INC6,072,103$214.7M
8DIMENSIONAL FUND ADVISORS LP4,522,378$159.9M
9Commodore Capital LP4,200,000$148.5M
10GEODE CAPITAL MANAGEMENT, LLC4,182,267$147.9M
11Deep Track Capital, LP3,590,323$127.0M
12JPMORGAN CHASE & CO4,101,789$123.7M
13WELLINGTON MANAGEMENT GROUP LLP2,970,166$105.0M
14FIRST TRUST ADVISORS LP2,968,785$105.0M
15PRIMECAP MANAGEMENT CO/CA/2,539,990$89.8M